Alexion, AstraZeneca Rare Disease Shares Phase 3 Ultomiris Trial Results
BOSTON, Mass., July 27, 2026 Alexion, AstraZeneca Rare Disease announced high-level results from its global Phase 3 clinical program...
ravulizumab
Advertisement
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
AstraZeneca’s Ultomiris Shows Phase 3 Breakthrough in IgAN
Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...
Advertisement
